Andrzej Wojtczak

Prof. Dr. Andrzej Wojtczak

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1996 in Acta Crystallographica Section D Structural Biology
Verified
Journal Article
Closed access
PDF file
AWAndrzej Wojtczak
Andrzej Wojtczak
VCV. Cody
V. Cody
JLJ. R. Luft
J. R. Luft
WPW. Pangborn
W. Pangborn

23 July 2001 in Acta Crystallographica Section D Structural Biology
Verified
Journal Article
Closed access
PDF file
NGNikolai Galitsky
Nikolai Galitsky
VCVivian Cody
Vivian Cody
AWAndrzej Wojtczak
Andrzej Wojtczak
DGDebashis Ghosh
Debashis Ghosh
JLJoseph R. Luft
Joseph R. Luft
LELeigh English
Leigh English

1 February 1996 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
MKMichał Komoszynski
Michał Komoszynski
AWAndrzej Wojtczak
Andrzej Wojtczak

26 April 2008 in Purinergic Signalling
Verified
Journal Article
Open access
PDF file
MCMarek Cieślak
Marek Cieślak
MKMichał Komoszyński
Michał Komoszyński
AWAndrzej Wojtczak
Andrzej Wojtczak
Latest results on the action of adenosine A2A receptor antagonists indicate their potential therapeutic usefulness in the treatment of Parkinson’s disease. Basal ganglia possess high levels of adenosine A2A receptors, mainly on the external surfaces of neurons located at the indirect tracts between the striatum, globus pallidus, and substantia nigra. Experiments with animal models of Parkinson’s disease indicate that adenosine A2A receptors are strongly involved in the regulation of the central nervous system. Co-localization of adenosine A2A and dopaminergic D2 receptors in striatum creates a milieu for antagonistic interaction between adenosine and dopamine. The experimental data prove that the best improvement of mobility in patients with Parkinson’s disease could be achieved with simultaneous activation of dopaminergic D2 receptors and inhibition of adenosine A2A receptors. In animal models of Parkinson’s disease, the use of selective antagonists of adenosine A2A receptors, such as istradefylline, led to the reversibility of movement dysfunction. These compounds might improve mobility during both monotherapy and co-administration with L-DOPA and dopamine receptor agonists. The use of adenosine A2A receptor antagonists in combination therapy enables the reduction of the L-DOPA doses, as well as a reduction of side effects. In combination therapy, the adenosine A2A receptor antagonists might be used in both moderate and advanced stages of Parkinson’s disease. The long-lasting administration of adenosine A2A receptor antagonists does not decrease the patient response and does not cause side effects typical of L-DOPA therapy. It was demonstrated in various animal models that inhibition of adenosine A2A receptors not only decreases the movement disturbance, but also reveals a neuroprotective activity, which might impede or stop the progression of the disease. Recently, clinical trials were completed on the use of istradefylline (KW-6002), an inhibitor of adenosine A2A receptors, as an anti-Parkinson drug.

1 May 2012 in Inorganica Chimica Acta
Verified
Journal Article
Closed access
SRSaeed Rayati
Saeed Rayati
NRNasim Rafiee
Nasim Rafiee
AWAndrzej Wojtczak
Andrzej Wojtczak

4 February 2015 in Acta Biochimica Polonica
Verified
Journal Article
Closed access
MCMarek Cieślak
Marek Cieślak
AWAndrzej Wojtczak
Andrzej Wojtczak
MCMichał Cieślak
Michał Cieślak
Several relations between cytokines and pathogenesis of diabetes are reviewed. In type 1 and type 2 diabetes an increased synthesis is observed and as well as the release of pro-inflammatory cytokines, which cause the damage of pancreatic islet cells and, in type 2 diabetes, the development of the insulin resistance. That process results in the disturbed balance between pro-inflammatory and protective cytokines. Pro-inflammatory cytokines such as interleukin 1β (IL-1β), tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), as well as recently discovered pancreatic derived factor PANDER are involved in the apoptosis of pancreatic β-cells. Inside β-cells, cytokines activate different metabolic pathways leading to the cell death. IL-1β activates the mitogen-activated protein kinases (MAPK), affects the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activates the inducible nitric oxide synthase (iNOS). TNF-α and IFN-γ in a synergic way activate calcium channels, what leads to the mitochondrial dysfunction and activation of caspases. Neutralization of pro-inflammatory cytokines, especially interleukin 1β with the IL-1 receptor antagonist (IL-1Ra) and/or IL-1β antibodies might cause the extinction of the inflammatory process of pancreatic islets, and consequently normalize concentration of glucose in blood and decrease the insulin resistance. In type 1 diabetes interleukin-6 participates in regulation of balance between Th17 and regulatory T cells. In type 2 diabetes and obesity, the long-duration increase of IL-6 concentration in blood above 5 pg/ml leads to the chronic and permanent increase in expression of SOCS3, contributing to the increase in the insulin resistance in cells of the skeletal muscles, liver and adipose tissue.